Boston Scientific

BSX · NYSE

$45.58+$0.53 (+1.18%)TodayMarket closed · Oct 20, 7:56 PM ET

Prev close $45.05

BSX analyst rating

BuyConsensus of 26 analysts over the last 12 months. 81% rate it a buy.

Strong buy0
Buy21
Hold5
Underperform0
Sell0

12-month price target · 33 analysts

Average $65.02 (+42.6% upside)

Low: $44.44
Now: $45.58
High: $123.90

Upgrades and downgrades

The latest rating actions, newest first

BSX analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Truist Securities	Oct 14, 2026	Maintains	Buy	$57.00 → $51.00	50%
Barclays	Oct 7, 2026	Initiates	Equal-Weight	$48.00	68%
Citigroup	Oct 5, 2026	Maintains	Neutral	$50.00 → $48.00	60%
Wells Fargo	Sep 24, 2026	Maintains	Equal-Weight	$50.00 → $48.00	54%
Oppenheimer	Sep 21, 2026	Maintains	Outperform	$85.00 → $65.00	44%
Citigroup	Sep 17, 2026	Downgrade	Buy → Neutral	$57.00 → $50.00	60%
BTIG	Sep 9, 2026	Maintains	Buy	$60.00 → $56.00	56%
TD Cowen	Aug 25, 2026	Maintains	Buy	$56.00	48%
Argus Research	Jul 31, 2026	Downgrade	Buy → Hold	—	66%
UBS	Jul 30, 2026	Maintains	Buy	$74.00 → $67.00	43%

The case for and against

Updated Oct 14, 2026

Bull case

Boston Scientific is benefiting from a steady cadence of new product launches and above-MedTech growth, with recent outperformance driven by rapid acceleration in electrophysiology from Farapulse pulsed field ablation. Its diversified portfolio has reduced reliance on commoditized cardiac rhythm management and drug-eluting stents, while Watchman, AGENT DCB, Lux-Dx, single-use scopes, LithoVue, and Rezum create multiple growth vectors and support a constructive long-term mix shift. Management’s constructive view on updated LAAO guidelines, plus FY27 estimates of $22.03B revenue and $3.40 EPS, alongside upside from Penumbra, ICE, and Seismiq, reinforce the case for sustained fundamental momentum.

Bear case

Boston Scientific is facing a deteriorating fundamental setup as the 8-day cybersecurity breach disrupted roughly 9% of revenue-producing days, forcing material cuts to Q3 and FY26 estimates and leaving some lost revenue unrecovered in key categories. The company’s 2026 outlook has been reset lower, with reported and organic sales growth now 5.5%-6.5% and 5%-6%, gross margin expected below 2025’s 70.6%, and only 0-25 bps of operating margin expansion versus 50-70 bps previously, while adj. EPS guidance fell to $3.28-$3.32. Beyond the outage, competitive pressure in LAAC and EP, utilization pressure in the U.S., and challenges in high-margin Watchman and U.S. EP weaken confidence in sustained organic growth and earnings durability.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.